Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from HilleVax, Inc ( (HLVX) ).
HilleVax, Inc. has been acquired by XOMA Royalty Corporation through a merger agreement, with the transaction completed on September 17, 2025. The acquisition involved a tender offer for all outstanding shares, which were converted into cash and contingent value rights, leading to HilleVax becoming a wholly owned subsidiary of XOMA. Following the merger, HilleVax’s shares will be delisted from Nasdaq, and the company will terminate its registration and reporting obligations under the Securities Exchange Act.
The most recent analyst rating on (HLVX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on HilleVax, Inc stock, see the HLVX Stock Forecast page.
Spark’s Take on HLVX Stock
According to Spark, TipRanks’ AI Analyst, HLVX is a Underperform.
HilleVax, Inc.’s stock score reflects significant risks due to its financial instability and absence of revenue. While technical indicators suggest some short-term momentum, the company’s reliance on external funding and negative cash flows present substantial challenges. The negative valuation metrics further indicate high risk, typical for early-stage biotech firms.
To see Spark’s full report on HLVX stock, click here.
More about HilleVax, Inc
Average Trading Volume: 678,822
Technical Sentiment Signal: Sell
Current Market Cap: $105.3M
Learn more about HLVX stock on TipRanks’ Stock Analysis page.